Graham Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Graham Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$340K	Sell	685 -1	-0.1%	-$443	0.01%	855
2026 Q1	$306K	Sell	686 -507	-42%	-$236K	0.01%	808
2025 Q4	$541K	Buy	+1,193	New	+$514K	0.01%	603
2025 Q1	–	Sell	-569	Closed	-$229K	–	1541
2024 Q4	$229K	Buy	+569	New	+$264K	﹤0.01%	1034
2024 Q2	–	Sell	-2,357	Closed	-$985K	–	1392
2024 Q1	$985K	Buy	2,357 +530	+29%	+$224K	0.02%	428
2023 Q4	$743K	Buy	+1,827	New	+$675K	0.02%	467
2023 Q3	–	Sell	-1,144	Closed	-$403K	–	1306
2023 Q2	$403K	Buy	+1,144	New	+$385K	0.01%	607
2022 Q4	–	Sell	-14,195	Closed	-$4.11M	–	1370
2022 Q3	$4.11M	Sell	14,195 -88	-0.6%	-$25.3K	0.16%	67
2022 Q2	$4.02M	Buy	14,283 +11,624	+437%	+$3.11M	0.16%	78
2022 Q1	$693K	Buy	2,659 +223	+9%	+$52.9K	0.02%	438
2021 Q4	$534K	Buy	+2,436	New	+$474K	0.02%	160

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Graham Capital Management's VRTX Position: Q2 2026 in Review

Graham Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.15% in Q2 2026, selling an estimated $443 and leaving 685 shares worth $340K. The position accounts for 0.01% of the portfolio, ranked #855.

Graham Capital Management first reported a position in VRTX in Q4 2021 and has held it in 11 quarters since. The position peaked at $4.11M in Q3 2022. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Graham Capital Management held 685 shares of Vertex Pharmaceuticals worth $340K as of Q2 2026.
Graham Capital Management sold 1 Vertex Pharmaceuticals share in Q2 2026, an estimated $443.
Vertex Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #855 holding.
Graham Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
Graham Capital Management's Vertex Pharmaceuticals position peaked at $4.11M in Q3 2022.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.